Jazz Pharmaceuticals Plc is a specialty biopharmaceutical company that identifies, develops, and commercializes medicines with a focus on narcolepsy, cancer, pain, and psychiatry. The company has a diverse portfolio of marketed medicines, including leading therapies for sleep disorders, epilepsy, and a growing portfolio of cancer treatments. It is dedicated to developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, to improve their quality of life.

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

COM:JAZZPHARMA

Cisco Systems Inc

Last Close

115.60

30/08 20:00

Market Cap

7.16B

Beta: -

Volume Today

330.50K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

invested in

Metrics